Friedreich ataxia: metal dysmetabolism in dorsal root ganglia by Arnulf H Koeppen et al.
Koeppen et al. Acta Neuropathologica Communications 2013, 1:26
http://www.actaneurocomms.org/content/1/1/26RESEARCH Open AccessFriedreich ataxia: metal dysmetabolism in dorsal
root ganglia
Arnulf H Koeppen1,2,3,4*, Erik C Kuntzsch1, Sarah T Bjork1, R Liane Ramirez1, Joseph E Mazurkiewicz5
and Paul J Feustel5Abstract
Background: Friedreich ataxia (FA) causes distinctive lesions of dorsal root ganglia (DRG), including neuronal
atrophy, satellite cell hyperplasia, and absorption of dying nerve cells into residual nodules. Two mechanisms may
be involved: hypoplasia of DRG neurons from birth and superimposed iron (Fe)- and zinc (Zn)-mediated oxidative
injury. This report presents a systematic analysis of DRG in 7 FA patients and 13 normal controls by X-ray
fluorescence (XRF) of polyethylene glycol-embedded DRG; double-label confocal immunofluorescence microscopy
of Zn- and Fe-related proteins; and immunohistochemistry of frataxin and the mitochondrial marker, ATP synthase
F1 complex V β-polypeptide (ATP5B).
Results: XRF revealed normal total Zn- and Fe-levels in the neural tissue of DRG in FA (mean ± standard deviation):
Zn=5.46±2.29 μg/ml, Fe=19.99±13.26 μg/ml in FA; Zn=8.16±6.19 μg/ml, Fe=23.85±12.23 μg/ml in controls. Despite
these unchanged total metal concentrations, Zn- and Fe-related proteins displayed major shifts in their cellular
localization. The Zn transporter Zip14 that is normally expressed in DRG neurons and satellite cells became more
prominent in hyperplastic satellite cells and residual nodules. Metallothionein 3 (MT3) stains confirmed reduction of
neuronal size in FA, but MT3 expression remained low in hyperplastic satellite cells. In contrast, MT1/2
immunofluorescence was prominent in proliferating satellite cells. Neuronal ferritin immunofluorescence declined
but remained strong in hyperplastic satellite cells and residual nodules. Satellite cells in FA showed a larger number
of mitochondria expressing ATB5B. Frataxin immunohistochemistry in FA confirmed small neuronal sizes, irregular
distribution of reaction product beneath the plasma membrane, and enhanced expression in hyperplastic satellite
cells.
Conclusions: The pool of total cellular Zn in normal DRG equals 124.8 μM, which is much higher than needed for
the proper function of Zn ion-dependent proteins. It is likely that any disturbance of Zn buffering by Zip14 and
MT3 causes mitochondrial damage and cell death. In contrast to Zn, sequestration of Fe in hyperplastic satellite
cells may represent a protective mechanism. The changes in the cellular localization of Zn- and Fe-handling
proteins suggest metal transfer from degenerating DRG neurons to activated satellite cells and connect neuronal
metal dysmetabolism with the pathogenesis of the DRG lesion in FA.
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Dorsal root ganglia (DRG) are a primary target of
Friedreich ataxia (FA) [1,2]. The reason for this vulner-
ability in comparison with other neural tissues is un-
known. The mutation in the vast majority of patients
with FA is a homozygous guanine-adenine-adenine
(GAA) trinucleotide repeat expansion in intron 1 of the
FXN gene that causes deficiency of frataxin, a small
mitochondrial protein [3]. A critical effect of low
frataxin levels is impaired function of iron (Fe)-sulfur
cluster-dependent proteins [4]. Little disagreement exists
that frataxin deficiency affects the function of mitochon-
drial complexes I, II, III, aconitase, and ferrochelatase,
and that frataxin-depleted cultured cells are abnormally
sensitive to reactive oxygen species. The role of Fe in
this sensitivity to oxidative damage has been more con-
troversial. Proponents and opponents have offered re-
cent reviews of the evidence for Fe [5] or against Fe [6].
While assay of total Fe in DRG of FA patients did not
show an increase above normal, prominent ferritin im-
munofluorescence in proliferating satellite cells sug-
gested enhanced ferritin messenger RNA (mRNA)
translation in response to local Fe excess [2]. The accu-
mulation of ferritin in satellite cells surrounding dying
DRG neurons, especially in the neuron-rich subcapsular
region of DRG, matched Fe-specific signals on X-ray
fluorescence (XRF) “maps” [2]. An upgraded version of
the XRF unit allows the operator to quantify Fe and
other metals in situ and to exclude DRG capsule, fat tis-
sue, and adjacent spinal roots that often contain concre-
tions of calcium (Ca), Fe, and Zn. XRF technology
recently established that the neural tissue of DRG con-
tains substantial concentrations of Zn. The importance
of Zn in DRG arises from the fact that this transition
metal is similar to Fe as a potential reactant in the syn-
thesis of hydroxyl radicals through Fenton chemistry.
This paper reports in-situ quantification of total Zn and
Fe, and changes in the metal-carrying proteins Zip14,
metallothionein (MT) 1/2 and 3, and ferritin in the DRG
of FA. It also describes the frataxin deficit in DRG at the
cellular level and the role of satellite cell hyperplasia in
the pathogenesis of the DRG lesion in FA.
Results
Autopsy specimens
This work has received approval by the Institutional Re-
view Board of the VA Medical Center, Albany, N.Y.,
USA. Table 1 lists basic clinical information on 7 FA pa-
tients from whom adequate DRG samples were available
for XRF and matching slide preparations. All patients
had homozygous GAA trinucleotide repeat expansions.
The cause of death was hypertrophic cardiomyopathy in
patients 2 and 4–7. Patients 1 and 3 died from cachexia
in the course of their neurological disability. Normalcontrol DRG tissue was available from 13 persons who
died from non-neurological illnesses. Mean age ± stan-
dard deviation (S.D.) was 62.5±9.1 years (range 48–77).
Autopsy delay was 16.3±10.9 h in the FA cases (range
3–33) and 22±20 h in the normal control subjects (range
1–56).
Qualitative and quantitative XRF of Zn and Fe
Figure 1 illustrates the alignment of Zn- and Fe-XRF
maps with matching sections respectively stained for
class-III-β-tubulin, Zip14, and ferritin. Mean concentra-
tions in μg/ml ± S.D. in 13 control subjects were
Zn=8.16 ± 6.19, Fe=23.85 ± 12.23. In 7 FA cases, they
were Zn = 5.46 ± 2.29 and Fe = 19.99 ± 13.26. The aver-
age in each subject was used for a statistical comparison
of metal concentrations by t-test which showed no dif-
ference between controls and FA. Figure 2 shows a lin-
ear regression analysis of Zn and Fe levels in all subjects.
Zn and Fe levels are significantly correlated. Multiple
linear regressions of control subjects and FA patients
disclosed no significant differences of slope or intercept.
Immunofluorescence and immunohistochemistry
Figure 3 shows the localization of class-III-β-tubulin and
Zip14 in DRG of a normal control and a case of FA by
double-label immunofluorescence. In normal DRG,
green class-III-β-tubulin immunofluorescence labels
neurons, dendrites, and axons, while red Zip14 fluores-
cence of variable intensity arises from the cytoplasm of
neurons and satellite cells. In FA, class-III-β-tubulin-
and Zip14-reactive nerve cells are much smaller, and
Zip14 fluorescence is more prominent in multiple layers
of satellite cells around atrophic neurons (Figure 3e).
Figure 4 presents a comparison of Zip14 and ferritin im-
munofluorescence. These proteins show extensive co-
localization in normal neurons and satellite cells though
ferritin immunofluorescence is more intense than Zip14
immunofluorescence in satellite cells. In FA, Zip14- and
ferritin-reactive nerve cells are smaller than normal, and
the central portions of neurons appear depleted. Ferritin
fluorescence arises prominently from multiple layers of
satellite cells and a residual nodule (Figure 4e). Figure 5
displays the disparate localization of MT1/2 and MT3
in normal and FA DRG. MT1/2 immunofluores-
cence arises exclusively from satellite cells. The single
perineuronal layer of MT1/2-positive satellite cells in
normal DRG (Figure 5a) changes to multiple layers in
FA (Figure 5d). In contrast, MT3 immunofluorescence is
most prominent in neuronal cytoplasm of normal DRG
though low-level emission also arises from satellite cells
(Figure 5b). In FA, MT3 immunofluorescence identifies
the cytoplasm of small DRG neurons but does not sug-
gest greater expression in hyperplastic satellite cells
(Figure 5e).
Table 1 Basic clinical information on 7 patients with FA from whom suitable DRG tissue was available for XRF
No. and sex Age of onset Age of death Disease duration GAA trinucleotide repeats
1 F 5 25 20 1100/800
2 M 7 34 27 1114/1114
3 M 7 35 28 1000/750
4 M 9 33 24 925/925
5 M 10 24 14 1050/700
6 F 15 69 54 568/568
7 F 18 63 45 730/639
Mean±S.D.* 10.1±4.7 40.4±18.1 30.3±14.2 927±205/785±185
*S.D., standard deviation.
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2 mm 2 mm









Figure 1 Alignment of Zn and Fe XRF maps of a DRG in FA and matching paraffin sections. (a), Zn XRF; (b), Fe XRF; (c) class-III-β-tubulin
immunohistochemistry; (d), ferritin immunohistochemistry; (e), Zip14 immunohistochemistry. Low-power photographs of the stained sections
were adjusted for size by reference to the mm scale on the XRF maps and rotated for optimal orientation. The illustrated DRG consisted of two
portions of neural tissue that were identified by class-III-β-tubulin (c) and Zip14 reaction products (e). The region-of-interest containing the bulk
of DRG neurons was outlined by interrupted lines. The outline was then transferred to the Zn and Fe XRF maps and the ferritin-stained section.
Maps were segmented by vertical and horizontal lines placed at 0.5 mm intervals over the images to generate a grid. Within the maps, each
square represented 0.25 mm2. At the edges, the squares were smaller. A single Zn or Fe signal was recorded as counts/10 sec from each square,
and results of all signals were averaged for each metal. After subtracting background XRF, averaged counts were converted to μg Zn or Fe per
ml PEG 1450. In the illustrated case of FA, Zn=4.8 μg/ml and Fe=33.4 μg/ml. The arrows in the two XRF maps indicate the location of Ti wires
that are visible on the Zn and Fe XRF maps, respectively, due to minor contamination by these metals. Note strong Zn and Fe XRF arising from
the capsule surrounding the neural portions of the DRG. These regions were effectively excluded from quantitative analysis by the illustrated
alignment. Bars, 2 mm.
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Figure 2 Correlation of Zn and Fe levels in DRG of 13 normal
controls and 7 cases of FA. Zn levels increase with Fe levels in
controls (closed back squares) and FA patients (open red circles).
Each symbol represents the mean Zn and Fe level in a single
subject, with horizontal and vertical lines representing the S.D. of Zn
and Fe determinations, respectively, within that subject. Mean and
S.D. are calculated from non-overlapping 0.25 mm2 areas in
controls and FA, covering the entire neural tissue region of DRG
(see methods). Regression result for all subjects is shown by the
dashed line: Zn = 0.81 + 0.285 × Fe; slope p<0.001; R2=0.45. Multiple
linear regression showed no significant difference between controls




Figure 3 Double-label immunofluorescence of class-III-β-tubulin and Z
normal control; (d)-(f) FA; (a) and (d) class-III-β-tubulin (Alexa488, green); (b
(a) shows large neurons that yield intense class-III-β-tubulin reaction produ
with less reaction product in the nerve cell marked by “N”. Anti-Zip14 also
neuron (d) continues to display Zip14 reaction product but is surrounded b
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S100α in satellite cells (Figure 6a) and the great abun-
dance of ATP synthase F1 complex V β-polypeptide
(ATP5B)-positive mitochondria (red) in the cyto-
plasm of normal DRG neurons (Figure 6b). Very little
ATP5B fluorescence is present in normal satellite cells
(Figure 6b-c). In contrast, the S100α-positive hyperplas-
tic satellite cells and residual nodule in FA display
abundant, finely granular, red ATP5B fluorescence
(Figure 6e-f ).
Figure 7 shows a comparison of frataxin and ATP5B
immunohistochemistry of a DRG in a normal control
and a patient with FA. In the normal control, granular
frataxin reaction product is present throughout the peri-
karya of all neurons, with very few reactive granules in
satellite cells (Figure 7a). In FA, the antibody reveals
smaller neurons, a paucity of granular reaction product
in neuronal cytoplasm, and a greater abundance of posi-
tive granules in satellite cells (Figure 7d). Pre-absorption
of the antibody with recombinant human frataxin elimi-
nates the reaction (Figure 7b and e). Incubation with an
antibody to the mitochondrial marker ATP5B yields a
very similar result: prominent granular staining of peri-
karya in normal DRG neurons (Figure 7c) and abundant




ip14 in a normal control DRG and a DRG of an FA patient. (a)-(c)
) and (e) Zip14 (Cy3, red); (c) and (f) merged images. The normal DRG
ct in perikaryon and dendrites. Zip14 staining (b) is heterogeneous,
visualizes satellite cells (b). In FA, a small class-III-β-tubulin-reactive






Figure 4 Double-label immunofluorescence of Zip14 and ferritin in a normal control DRG and a DRG of an FA patient. (a)-(c) normal
control; (d)-(f) FA; (a) and (d) Zip14 (Alexa488, green); (b) and (e) ferritin (Cy3, red); (c) and (f) merged images. Zip14 (a) and ferritin reaction
products (b) show co-localization in the cytoplasm of several large and small neurons and in perineuronal satellite cells (arrows). Zip14 and
ferritin fluorescence in neurons is heterogeneous. In the FA case (d-f), neuronal Zip14 (d) and ferritin (e) have shifted to a location beneath the
plasma membrane while the central portion of the nerve cells (N) is devoid of reaction product. Zip14 fluorescence is present in satellite cells and
a residual nodule (d, arrow). Ferritin fluorescence in multi-layer satellite cells and a residual nodule (e, arrow) is very prominent. Bars, 20 μm.
a 
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Figure 5 Double-label immunofluorescence of MT1/2 and MT3 in a normal control DRG and a DRG of an FA patient. (a)-(c) normal
control; (d)-(f) FA; (a) and (d) MT1/2 (Alexa488, green); (b) and (e) MT3 (Cy3, red); (c) and (f) merged images. MT1/2 immunoreactivity is restricted
to normal (a) and hyperplastic satellite cells in FA (d). MT3 immunofluorescence is localized in the cytoplasm of a normal large DRG neuron
(b) and in satellite cells, in which it co-localizes with MT1/2 (a-c, arrows). In FA (e), one of three small DRG neurons shows very little MT3
immunofluorescence (N) while two others remain strongly fluorescent. The thickened layers of satellite cells around the 3 neurons show relatively
low MT3 fluorescence (e). Bars, 20 μm.
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Quantitative in-situ determination of Zn and Fe in DRG
Systematic quantification of Zn in fresh or frozen aut-
opsy specimens of normal DRG has not been reported.
Total levels of Fe in DRG of FA patients and normal
control subjects, however, are available [2]. Levels were
25.4±10.3 μg/g wet weight (mean ± S.D.) in 3 samples
from FA patients and 28±13.4 μg/g wet weight (mean ±
S.D.) in 8 normal controls. The difference was not sig-
nificant. These results are now less applicable because
the new method utilizing XRF can restrict measure-
ments to neural tissues of DRG (Figure 1). While the
relatively coarse steps (0.15 mm) of the scanning XRF
instrument do not resolve the cellular localization of Zn
or Fe, non-destructive XRF technology allows for intact
tissue samples to be recovered, re-embedded in paraffin,
sectioned, and stained for class-III-β-tubulin, Zip14, and
ferritin. The critical step is matching XRF metal maps
with stained tissue sections. Infiltration by PEG 1000
and PEG 1450 displaces all tissue water, and results
expressed as μg metal/ml PEG 1450 (Figure 2) are
equivalent to μg metal/ml tissue volume. The results of
Zn and Fe can be converted to μg/g wet tissue weight by
assuming DRG water content of at least 80 percent.
When the mean XRF-recorded Fe levels in normal DRG
(23.85 μg/ml PEG) and DRG of FA (19.99 μg/m PEG)
are multiplied by 0.8, the result yields 19.08 μg/g wet
weight for controls, and 16 μg/g wet weight for FA.
These concentrations are lower than the chemical assay
of whole DRG [2], reflecting the exclusion of capsule
and pericapsular tissues by XRF technology.
Localization of Zn, Fe, and metal-related proteins in DRG
The normal human DRG may be similar to rat DRG, in
which Pérez-Castejón et al. [7] visualized Zn in the cyto-
plasm of neurons by histochemistry and autoradiog-
raphy. Velázquez et al. [8] also detected the metal by
fluorescence microscopy and MT3 by immunofluores-
cence in rat DRG. Autolysis due to delayed autopsy
imposes severe limitations on the visualization of Zn
by chemical and metallographic methods. None of the
DRG specimens obtained from the FA patients listed in
Table 1 were fixed within the optimal time limit of
under 2 h [9,10]. Therefore, this research utilized the
immunodetection of Zip14, MT1/2, and MT3 as surro-
gate markers of Zn, and ferritin as a marker of Fe. The
intensity of Zip14 (Figures 3b and 4a) and MT3 im-
munofluorescence (Figure 5b) suggests that the bulk of
Zn in normal DRG is located in the cytoplasm of neu-
rons. In contrast to MT3, the more restrictive immuno-
fluorescence of MT1/2 (Figure 5a and d) implies that
this protein provides Zn homeostasis in normal
(Figure 5a) and hyperplastic satellite cells (Figure 5d).
While ferritin immunofluorescence is stronger insatellite cells than in neurons (Figure 4b), ferritin signal
is also present in neurons where it co-localizes with
Zip14 (Figure 4a).
Supportive evidence of Zn and Fe translocation in FA
The described observations establish that FA causes
neither influx nor efflux of DRG Zn or Fe. Changes due
to FA, however, are evident by immunofluorescence
of several metal-handling proteins. The response of
Zip14- and ferritin-immunoreactivity to FA is similar,
suggesting the transition of Zn and Fe from degenerating
neurons to satellite cells occurs by comparable mecha-
nisms. It is likely that MT1/2 reacts to the transfer of Zn
from neurons to satellite cells while MT3 remains re-
stricted to smaller neurons (Figure 5e) and presumably
disappears when atrophic nerve cells are totally absorbed
into residual nodules.
Heretofore, MT3 was thought to be a unique central
nervous system (CNS) protein [11], but its presence in
DRG (Figure 5b) suggests that neuronal Zn homeostasis
is similar.
In CNS, the most prominent Zn transporter is ZnT3,
which packages Zn into synaptic vesicles (review in ref
[9]). As expected, an antibody to ZnT3 did not generate
an immunohistochemical reaction in DRG, which under
normal circumstances are devoid of synapses. Zip trans-
porters, including Zip14, are not specific for Zn, and it is
noteworthy that the “i” in Zip derives from “iron”
[12,13]. Zip14 and MT3 may collaborate in Zn homeosta-
sis of normal DRG neurons. While MT3 is a Zn storage
and buffering protein, Zip14 adds Zn transport across
plasma membranes. In some DRG neurons of FA, Zip14
immunofluorescence localizes to the cytoplasm just be-
neath the plasma membrane (Figure 4d). The transmem-
brane localization of functional Zn transporters may be
relevant to this pathological phenomenon.
Origin and physiological role of Zn in normal human
DRG are unknown. Velázquez et al. [8] reported that Zn
in rat DRG may arise from retrograde axonal transport
through dorsal spinal roots. It accumulated only in
small-diameter DRG neurons, and the authors [8] con-
sidered a role in sensory processing. In humans with FA,
loss of Zn-containing DRG neurons may contribute to
the complex pathological phenotype observed in dorsal
roots [2] and sensory peripheral nerves [14].
The role of satellite cells in FA
The greater abundance of satellite cells in FA accounts
for the hypercellularity of DRG that is readily apparent
on routine cell stains [2]. It is likely that the earliest
response to the disease is the formation of multiple
layers of satellite cells about neurons. This phenomenon
is especially apparent by ferritin (Figure 4e) and MT1/2
immunofluorescence (Figure 5d). Residual nodules
cba
d fe
Figure 6 Double-label immunofluorescence of S100α and ATP5B in a normal control DRG and a DRG of an FA patient. (a)-(c) normal
control; (d)-(f) FA; (a) and (d) S100α (Alexa488, green); (b) and (e) ATP5B (Cy3, red); (c) and (f) merged images. S100α immunofluorescence is a
robust marker of normal satellite cells (a) and hyperplastic satellite cells in FA (d). In the normal DRG, ATP5B fluorescence is prominent in
neuronal cytoplasm (b), and only sparse reaction product is present in the tissue between neurons. In contrast, satellite cells in FA (e) show a
great abundance of granular ATP5B immunofluorescence. The arrows in (d)-(f) indicate a residual nodule. Bars, 20 μm.
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sia beyond death of the neuron, but there is no insight
yet about the fate of these cellular collections or whether
they ultimately shed Zn and Fe into the blood stream.
In normal DRG, neuronal and satellite cell plasma
membranes are very closely apposed, with multiplea
ed
b
Figure 7 Frataxin and ATP5B immunohistochemistry of a normal con
FA; (a) and (d) frataxin; (b) and (e) anti-frataxin antibody pre-absorbed by h
granular frataxin reaction product fills the perikarya of all neurons (a). React
yields a similar result (c). In FA (d-f), frataxin reaction product in small neur
hyperplastic satellite cells display more frataxin-reactive granules than norm
hyperplastic satellite cells, and a residual nodule that resembles frataxin (f,invaginations in both directions [15]. Also, satellite cells
are tightly linked to each other. Beyond structural sup-
port, they handle “trafficking” into and out of DRG neu-
rons. Pannese [15] also cited experimental studies, in
which satellite cells provided “trophic support” to neu-
rons. FA is typically a disease of nerve cells in the centralf
c
trol DRG and a DRG of an FA patient. (a)-(c) normal control; (d)-(f)
uman recombinant frataxin; (c) and (f) ATP5B. In the normal DRG,
ion product in satellite cells is sparse. ATP5B immunohistochemistry
ons is concentrated under the neuronal plasma membrane, and
al (d). In FA, ATP5B reaction product shows a distribution in neurons,
arrow). Two neurons are outlined by interrupted lines. Bars, 20 μm.
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therefore be similarly vulnerable to frataxin deficiency. It
is a theoretical consideration that hyperplastic satellite
cells, which also derive from the neural crest, do not ad-
equately support their immediately adjacent neurons,
and neuronal atrophy may be secondary.
The greater abundance of mitochondria in hyperplas-
tic satellite cells and residual nodules in DRG of FA
indicates that these cells develop a more active oxida-
tive metabolism as part of the pathological phenotype
(Figures 6e and 7f). In normal DRG, satellite cells con-
tain few mitochondria (Figure 6b-c) whereas reaction
product of ATP5B is very abundant in the closely ap-
posed neuron. In promptly fixed normal DRG, the avail-
able monoclonal anti-frataxin antibody shows reaction
product that strongly resembles the distribution of the
mitochondrial marker ATP5B (Figure 7). It is apparent
that lack of frataxin does not impair the proliferation of
satellite cells and the processing of the protein to its ma-
ture functional form [16].
Endogenous metal toxicity or epiphenomenon?
A key question in the pathogenesis of the DRG lesion in
FA is: Do Zn and Fe in the cytosol of neurons become
toxic, or is the shift in metal-related proteins an epiphe-
nomenon of frataxin deficiency? Human autopsy tissues
do not lend themselves to the direct measurement of
toxic radicals, but changes in the cellular localization of
Zip14, MT1/2, MT3, and ferritin suggest a disturbance
is Zn and Fe homeostasis. In the absence of a synaptic
source of Zn, the mechanism of toxicity in DRG neurons
may be similar to that in CNS neurons of ZnT3-deleted
animals [17]. In the cytosol of CNS neurons, ionic Zn
must be kept at picomolar or femtomolar levels to pre-
vent toxicity and still meet metabolic demands [18]. It is
likely that neurons in normal DRG maintain Zn homeo-
stasis by buffering proteins such as MT3 (Figure 5b) and
by sequestration of the metal in mitochondria [18]. The
mean level of 8.16 μg/ml in normal DRG, reported in
this study, is equal to a concentration of 124.8 μM.
Neuronal toxicity is thought to occur at ionic Zn2+ levels
in the range of 100 nM to 3 μM [18]. Therefore, the
total pool of neuronal Zn in DRG is present in large ex-
cess over need, and control mechanisms must be very
efficient. Dineley et al. [19,20] summarized the evidence
of endogenous Zn toxicity in the CNS, in which mito-
chondria bear the brunt of the damage. Mitochondrial
impairment has many untoward effects: insufficient bio-
synthesis of adenosine triphosphate; decrease of mito-
chondrial membrane potential; release of cytochrome C
and apoptosis-inducing factor; and generation of reactive
oxygen species and nitric oxide [18]. All of these pro-
cesses ultimately cause cell death. If they exist in FA
in vivo, the untoward effects of Zn on DRG neurons aresuperimposed on deficient oxidative phosphorylation,
which is a recognized effect of frataxin deficiency [4]. Fe
in DRG may be less injurious than Zn because
holoferritin has a prodigious ability to trap the metal.
Therefore, the aggregation of Fe in the shell of ferritin in
hyperplastic satellite cells may be protective against Fe-
mediated oxidative injury.
Based on experiments with frataxin-deleted mice [21],
human neonates with homozygous mutations of the
FXN gene must have at least some normal frataxin to
survive to the mean age of death (40±20 years [N=30;
mean ± S.D.]; ref. [22]). It is likely that DRG are hypo-
plastic at birth in all patients with mutated FXN genes
[1,2,23]. A superimposed atrophic process may lead to
progressive destruction of neurons, principally by satel-
lite cell invasion and absorption into residual nodules.
This transition may be the reason why clinical “onset” of
FA is delayed to a mean age of 15 years [24]. It may be
proposed that in DRG, Zn and Fe dysmetabolism con-
tribute to onset and progression. In contrast to brain,
however, nothing is known about the rate by which
DRG acquire Zn and Fe during growth. Extrapolating
from human brain, it is unlikely that end-point Zn accu-
mulation in DRG coincides with onset of FA [25].
Many questions remain: Does frataxin deficiency trig-
ger endogenous metal toxicity; and why do DRG in FA
retain Zn and Fe rather than shedding the metals into
the blood stream? The hypothesized accelerated DRG
destruction by endogenous metals does not contradict
other potential mechanisms of increasing disease activ-
ity, such as somatic GAA expansion in postmitotic neu-
rons through the activity of mismatch repair enzymes
[26] or greater epigenetic gene silencing [27].
Conclusions
The neural tissue of DRG contains measurable levels of
Zn and Fe. During progressive destruction of DRG in
FA, these metals are retained rather than discharged into
the circulating blood. Enhanced expression of Zip14,
MT1/2, and ferritin in hyperplastic satellite cells of DRG
in FA represents indirect evidence that Zn and Fe are
lost from degenerating neurons. Metabolic activation of
satellite cells in FA is evident by the accumulation of
ATP5B-expressing mitochondria. Failing metal homeo-
stasis in DRG neurons may contribute to endogenous
Zn toxicity whereas Fe sequestration in holoferritin of
hyperplastic satellite cells may be neuroprotective.
Methods
Polyethylene glycol embedding of specimens
After fixation in buffered 4% formaldehyde solution for
at least 10 days at 4°C, DRG were divided into two por-
tions. One portion was directly embedded in paraffin;
the other portion was infiltrated by polyethylene glycol
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immersed at room temperature in aqueous solutions of
increasing concentrations (30-90%) of PEG 400 (Sigma,
St. Louis, MO, USA), followed by PEG 1000 and PEG
1450 at 60°C. After cooling overnight, PEG 1450 blocks
containing DRG tissues were trimmed and “faced” by
microtome to present a smooth surface for scanning by
XRF. Four segments of titanium (Ti) wire were inserted
into the PEG blocks, a short distance from the tissue, to
mark the scanning limits of the XRF instrument. Low level
Zn and Fe contamination (0.01 percent) in the Ti wires
generated Zn and Fe XRF that aided in the subsequent
alignment of maps and tissue sections.
XRF of PEG-embedded DRG and Zn and Fe standards
The custom-built XRF machine consisted of a glass-
enclosed chamber housing a molybdenum target X-ray
tube, X-ray optics with a doubly-curved crystal, an x-y co-
ordinate scanning mechanism, and a silicon-drift detector
[28]. Zn- and Fe-specific XRF was generated with a triple
X-ray beam over a period of 10 sec per location with scan-
ning steps of 0.15 mm. The recorded XRF was converted
to “maps” of Fe and Zn by the use of a Windows-based
proprietary computer program. Pseudocolors indicated
relative XRF intensities, with maximum fluorescence as
white. Red, orange, green, and light blue represented pro-
gressively lower signal strengths. Fe and Zn calibration
standards were prepared from Fe-III-mesoporphyrin and
Zn-II-mesoporphyrin, respectively, and validated by elem-
ental analysis as described before [28].
Recovery of DRG from PEG 1450
PEG-embedded DRG tissue was recovered by immersion
in phosphate-buffered saline (PBS) and repeated washing
in PBS at room temperature (RT). The tissue was post-
fixed for several hours at RT in buffered 4% formaldehyde
solution (pH 7.2) and embedded in paraffin by routine
methods. Six-μm-thick sections were stained by immu-
nohistochemistry with antibodies to class-III-β-tubulin,
Zip14, and ferritin as described below.
Alignment of DRG sections with Zn and Fe maps, and
quantitative measurement of Zn and Fe
Low-power photographs (1.25×) of DRG sections stained
for class-III-β-tubulin, Zip14, and ferritin were matched to
the Zn and Fe XRF maps as shown in Figure 1. The neural
tissue of the DRG was outlined based on class-III-β-tubu-
lin and Zip14 reaction product. The limiting outline was
transferred to the aligned Zn- and Fe-XRF maps to ex-
clude signals arising from non-neural tissues, and to the
ferritin-stained section. Zn and Fe maps were segmented
in steps of 0.5 mm by the insertion of vertical and hori-
zontal lines. Each square represented 0.25 mm2. Depend-
ing on the size of the available tissue sample, this methodgenerated 21–111 squares for the 13 normal DRG and
12–64 squares for the 7 DRG of FA cases. Zn and Fe XRF
in each square were recorded as counts/10 sec, and aver-
age and standard deviation (S.D.) were determined for
each individual. An equal number of locations outside the
region defined by the Ti wires were used to determine
background XRF. After subtracting background XRF from
the Zn- and Fe-signals, counts were converted to μg/ml
PEG by reference to calibration standards.
Antisera, antibodies, antigen retrieval methods,
immunohistochemistry, and immunofluorescence
The following antisera (antibodies) were available for
immunohistochemistry or immunofluorescence (host
species, type of antibody, and commercial source in par-
entheses): ferritin (rabbit polyclonal, DAKO, Carpinteria,
CA, USA; goat polyclonal, GenWay Biotech, San Diego,
CA, USA); class-III-β-tubulin (mouse monoclonal anti-
body TUJ-1, R&D Systems, Minneapolis, MN, USA);
Zip14 (rabbit polyclonal, Novus Biological, Littleton,
CO, USA); MT1/2 (mouse monoclonal, Invitrogen, Fred-
erick, MD, USA); MT3 (rabbit polyclonal, Sigma-Aldrich,
St. Louis, MO, USA); ATP5B (rabbit polyclonal, Santa
Cruz Biotechnology, Santa Cruz, CA, USA); S100α
(mouse monoclonal, Santa Cruz); frataxin (mouse mono-
clonal, Mitosciences, Eugene, OR, USA). The MT
isoforms 1 and 2 show extensive amino acid homology.
The monoclonal antibody reacts with both proteins,
hence, the designation “MT1/2”. Optimal antibody dilu-
tions were determined by trial and error, and protein
concentrations ranged from 0.2-50 μg protein/ml. Immu-
nohistochemical and immunofluorescence protocols
were described in detail in previous publications [2,23,28].
Antigen retrieval methods were DIVA (a proprietary
decloaking solution marketed by Biocare Medical,
Concord, CA, USA) for 30 min at 95°C for ferritin; incu-
bation in 0.01 M citric acid/sodium citrate buffer (pH 6)
for 20 min at 95°C for class-III-β-tubulin, S100α, MT1/2,
and MT3; and incubation in 0.1 M tris buffer (pH 9.5)
for 20 min at 95°C for ATP5B and frataxin. A chelating
step with 2,2′-dipyridyl and sodium hydrosulfite (30 mM
each in 0.1 M acetic acid-sodium acetate buffer, pH 4.8)
was included for the visualization of ferritin and frataxin.
The specificity of frataxin immunohistochemistry was con-
firmed by preincubation of the antibody solution with a 4-
fold excess of recombinant human frataxin (by concentra-
tion of protein). Biotinylated secondary antibodies came
from Vector Labs (Burlingame, CA, USA). Sigma-Aldrich
supplied horseradish peroxidase-labeled streptavidin. Paraf-
fin sections were also used for double-label laser confocal
scanning immunofluorescence microscopy of the pairs
MT1/2/MT3; Zip14/class-III-β-tubulin; Zip14/ferritin; and
S100α/ATP5B. Fluorescently labeled donkey anti-rabbit
and anti-mouse IgG antibodies (Alexa488 and Cy3) were
Koeppen et al. Acta Neuropathologica Communications 2013, 1:26 Page 10 of 10
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PA, USA). The laser scanning confocal microscope was a
Zeiss LSM 510 Meta unit. The exciting wavelengths for
Alexa488 and Cy3 were 488 and 543 nm, respectively. Im-
ages were obtained at a magnification of 63× under oil
immersion and through band pass filters of 500–530 nm
for Alexa488 and 565–615 nm for Cy3.
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